Yale University School of Medicine.
Blood. 2020 Aug 6;136(6):655-656. doi: 10.1182/blood.2020007483.
In this issue of , Berzuini et al describe immunoglobulin G (IgG) bound to the red blood cells (RBCs) of patients with COVID-19 and associate this bound IgG with increased RBC transfusion requirements. The intrigue behind these observations is not just the high (46%) direct antiglobulin test (DAT) positivity rate, but also the novel finding that eluates (ie, antibodies stripped from the surface of the reactive RBCs) from these DAT-positive patients react not with standard-reagent RBCs but exclusively with RBCs from DAT-negative COVID-19 patients.
本期 杂志中,Berzuini 等人描述了 COVID-19 患者红细胞(RBC)上结合的免疫球蛋白 G(IgG),并将这种结合的 IgG 与 RBC 输血需求增加联系起来。这些观察结果背后的吸引力不仅在于高(46%)的直接抗球蛋白试验(DAT)阳性率,还在于一个新发现,即从这些 DAT 阳性患者中洗脱的(即,从反应性 RBC 表面去除的抗体)洗脱物与标准试剂 RBC 不反应,而仅与 DAT 阴性 COVID-19 患者的 RBC 反应。